INS and type 2 diabetes mellitus: This advantage foronce-weekly insulins manifested itself in the results from the icodec phase 3 program, whichdemonstrated superior HbA1c reduction compared to both IGlar U100 and IDeg atprimary end point in 4 of the 5 studies in T2D patients (115-119).